1LjungmanS,WiksrandJ,HartfordM,etal.Prognostic value of microalbuminuria in untreated hypertensive and normotensive non-diabetic subjects followed for 10 years.Am J Hypertens,1996,9:770-778.
2AmlovJ,EvansJC,MeigsJB,etal.Low-Grade Albuminuria and incidence of cardiovascular disease events in nonhypertesive and nondiabetic individuals.The Framingham Heart Study.Circulation,2005,112:969-975.
3Jensen JS,Feldr-Rasmussen B,Strandgaards,et al.Microalbuminuria predicts coronary events in subjects with essential hypertension.Hypertens,2000,35:898 -903.
4Yusuf S,Sleight P,Pogue J,et al.Effects of an angiotensin convertingenzyme inhibitor,ramipril,on cardiovascular events in high risk patients.The heart outcomes prevention evaluation study investigators.N Engl J Med,2000,342:145-153.
5Klausen KP,Scharling H,Jensen G,et al.New definition of microalbuminuria in hypertensive subjects association with incident coronary heart disease and death.Hypertens,2005,46:33-37.
6Taal MW,Brnner BM.Combination ACEI and ARB therapy:additional benefit in renoprotection? Current Opin in Nephrology and Hypertens,2002,11:377-381.
7Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med,2001,345:870-878.
8Mogensen CE,Neldam S,Tikkanen I,et al.Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension,microalbuminuria,and non-insulin dependent diabetes:the candesartan and lisinopril microalbuminuria (CALM) study.BMJ,2000,321:1440-1444.
9Geluk CA,Asselbergs FW,Hillege HL,et al.Impact of statins in microalbuminuric subjects with the metabolic syndrome:a substudy of the PREVEND intervention trial.Eur Heart J,2005,26:1314-1320.
8American Society of Hypertension Writing Group.Combination therapy in hypertension[J].J Am Soc Hypertens,2010,4(1):42-50.
9The ONTARGET Investigators. Tehnisartan, ramipril, or both in patients at high risk for vascular events [J]. N Engl J Med,2008,358:1547-1559.
10KYOTO HEART Study Group.Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [J] .European Heart Journal, 2009,30(20) : 2461-2469.
